Jyong Biotech Ltd.
MENSNasdaq
$2.26
↓ -1.7%Jul 17 close · end-of-day
Price
1Y↓ -80.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$165.0M
Enterprise Value
$182.5M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$4.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
18.8%
ROIC
—
Debt / Equity
-0.7
Net Cash
-$17.5M
Return 1Y
-79.5%
Company profile
We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia. Our principal executive offices of our operating subsidiaries are located in New Taipei City, Taiwan.
- CEO
- Fu-Feng Kuo
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 31
- Website
- www.healtheverbiotech.com
Earnings
No reported earnings periods on file.
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$2.8M | -$2.1M | -$2.6M |
| Net income | -$4.4M | -$3.0M | -$4.7M |
| Diluted EPS | -$0.06 | -$0.04 | -$0.06 |
| Operating cash flow | -$2.6M | -$3.6M | -$3.0M |
| Free cash flow | — | — | — |
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
No quarterly data.
Company news
May 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.